NCT01326702 2019-12-16Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsNational Cancer Institute (NCI)Phase 1/2 Completed43 enrolled 18 charts
NCT01429025 2019-10-08Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaAlliance for Clinical Trials in OncologyPhase 1 Completed26 enrolled
NCT01110135 2017-05-24Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaUniversity of WashingtonPhase 2 Completed43 enrolled 5 charts